• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Immunology call at 5:30









































Some of the above posters have no idea what they are talking about. The only immunology salesforce affected was HS. They were cut but they had already been changing to contract salesforce for the past year. For the rest (derm outside of HS, rheum, gastro), there were no cuts to leadership, training, or sales. Rheum actually expanded salesforce.

maybe more cuts in the future if RINVOQ does not perform but minimal impact as of now